FIG. 7.

HIV-1-suppressive activity of the heparin-bound eluates (A), silver-stained SDS-polyacrylamide gel of peak active suppressive fraction (B), and Western blot of peak active suppressive fraction, using a combination of antibodies against IL-16, MDC, and I-309 (C). (A) Heparin-bound eluates were diluted 1:30 in the inhibition test (see Materials and Methods). At day 9, HIV-1 p24 antigen was measured and compared against a buffer-treated control. (B) Lane 1, 20 μl of fraction with peak suppression was subjected to SDS-PAGE and silver stained. (C) Lane 1, Western blot of 20 μl of fraction with peak suppression (1/5 of total amount used for the 9-day inhibition test) incubated with the combined antibodies; lane 2, Western blot of the IL-16 protein (100 ng) incubated with combined antibodies; lane 3, Western blot of MDC protein (100 ng) incubated with combined antibodies; lane 4, Western blot of the I-309 protein (100 ng) incubated with combined antibodies. In control experiments, the Western blots were incubated alone with antibodies against IL-16, MDC, and I-309. AU, arbitrary units.